Basic therapeutic approaches to the management of hematology/oncology patients with new coronavirus infection (COVID-19)

In December 2019, cases of severe respiratory infection were reported in Wuhan, China. The disease was caused by a new, previously undescribed coronavirus, structurally similar to the then known SARS-CoV virus. The World Health Organization has named the new virus SARS-CoV-2 and the disease it causes COVID-19. The problem of COVID-19 is exacerbated by the rapid spread of the SARS-CoV-2 virus and the development of life-threatening complications, the main of which is pneumonia. Due to the severity of the condition, from 5 to 10 % of patients are treated in intensive care units.

SARS-CoV-2 initially attacks the respiratory system and causes symptoms such as fever, vomiting, headache, dizziness, general weakness, and diarrhea. Then these symptoms intensify in different directions, and the disease can often lead to death.

Initially, only a few methods of symptomatic treatment were available and clinical trials of drugs that had previously shown their effectiveness against infection with the MERS-CoV and SARS-CoV viruses began. Temporary recommendations have appeared suggesting the use of some drugs both in monotherapy and in combination.

In patients with hematologic malignancies, the immune response to the SARS-CoV-2 coronavirus is significantly reduced, which explains the high mortality rate (up to 38 %) of these patients hospitalized for SARS-CoV-2 infection. Recently, antiviral drugs and monoclonal antibodies have become available for pre- or post-exposure prophylaxis, as well as for early treatment of COVID-19. These treatments should be offered to patients at high risk of severe COVID-19 and to those who have not responded to vaccination. However, as changes in the genetic structure of the virus accumulate, some treatments may lose their clinical effectiveness against new variants.

The combination of hematological malignancies and new coronavirus infection causes a more severe course of COVID-19 compared to the population and high mortality. Factors for an unfavorable prognosis for new coronavirus infection in patients with hematological malignancies include age over 60 years, a high comorbidity index, diagnoses such as acute leukemia, especially acute myeloid leukemia and myelodysplastic syndrome, disease status (relapse, progression, as well as newly diagnosed acute leukemia), severe COVID-19, agranulocytosis (myelotoxic or tumor).

1. Xiong J., Lipsitz O., Nasri F. et al. Impact of COVID­19 pandemic on mental health in the general population: a systematic review. J Affect Disord 2020;277:55–64. DOI: 10.1016/j.jad.2020.08.001

2. Ksiazek T.G., Erdman D., Goldsmith C.S. et al. A novel coronavirus associated with severe acute respiratory syndrome Thomas. N Engl J Med 2020;348(20):1953–66. DOI: 10.1056/NEJMoa030781

3. Bhatraju P.K., Ghassemieh B.J., Nichols M. et al. Covid-­19 in critically ill patients in the Seattle region – case series. N Engl J Med 2020;382(21):2012–22. DOI: 10.1056/NEJMoa2004500

4. Chen N., Zhou M., Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223): 507–13. DOI: 10.1016/S0140­6736(20)30211­7

5. Guan W., Ni Z., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708–20. DOI: 10.1056/nejmoa2002032

6. Memish Z.A., Zumla A.I., Al­Hakeem R.F. et al. Family cluster of middle east respiratory syndrome coronavirus infections. N Engl J Med 2013;368:2487–94. DOI: 10.1056/nejmoa1303729

7. Langerbeins P., Hallek M. COVID­-19 in patients with hematologic malignancy. Blood 2022;140(3):236–52. DOI: 10.1182/blood.2021012251

8. https://covid19.who.int/.

9. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

10. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID­-19). Version 14. Russian Ministry of Health, 27.12.2021 (In Russ.). Available at: http://static.consultant.ru/obj/file/doc/minzdrav_271221.pdf.

11. Horby P., Lim S., Emberson J.R. et al. Dexamethasone in hospitalized patients with Covid-­19 – preliminary report. N Engl J Med 2021;384(8):693–704. DOI: 10.1056/NEJMoa2021436

12. Wong C.K., Lam C.W.K., Wu A.K.L. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004;136(1):95–103. DOI: 10.1111/j.1365­2249.2004.02415.x

13. Baillie J.K., Digard P. Influenza – time to target the host? N Engl J Med 2013;369(2):191–3. DOI: 10.1056/NEJMcibr1304414

14. Moore J.B., June C.H. Cytokine release syndrome in severe COVID­-19. Science 2020;368(6490):473–4. DOI: 10.1126/science.abb8925

15. Ye Q., Wang B., Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID­19. J Infect 2020;80(6):607–13. DOI: 10.1016/j.jinf.2020.03.037

16. Frolova N.F., Tomilina N.А., Loss K.E. et al. The use of therapeutic plasma exchange in the severe forms of COVID-­19 in patients with renal fаilure. Nefrologiya i dializ = Nephrologу and Dialуsis 2022; 24(2):279–91. (In Russ.). DOI: 10.28996/2618­9801­2022­2­279­291

17. Tabibi S., Tabibi T., Conic R.R.Z. et al. Therapeutic plasma exchange: a potential management strategy for critically ill COVID­-19 patients. J Intensive Care Med 2020;35(9):827–35. DOI: 10.1177/0885066620940259

18. Chang J.C. Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease. Thromb J 2019;17:10. DOI: 10.1186/s12959­019­0198­4

19. Pujari R., Thommana M.V., Ruiz Mercedes B. et al. Therapeutic options for COVID-­19: a review. Cureus 2020;12(9):e10480. DOI: 10.7759/cureus.10480

20. Keith P., Day M., Perkins L. et al. Wells a novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-­19. Critical Care 2020;24:128. DOI: 10.1186/s13054­020­2836­4

21. Balagholi S., Dabbaghi R., Eshghi P. et al. Potential of therapeutic plasmapheresis in treatment of COVID­19 patients: immunopathogenesis and coagulopathy. Transfus Apher Sci 2020;59(6):102993. DOI: 10.1016/j.transci.2020.102993

22. Treatment protocol for hospitalized patients with COVID­-19 at the “City Clinical Hospital No. 52”. Order No. 871 dated 02.12.2021. (In Russ.).

23. Kim J.S., Lee J.Y., Yang J.W. et al. Immunopathogenesis and treatment of cytokine storm in COVID­19. Theranostics 2021;11(1):316–29. DOI: 10.7150/thno.49713

24. Clark W.F., Huang S.H.S., Walsh M.W. et al. Plasmapheresis for the treatment of kidney diseases. Kidney Int 2016;90:974–84. DOI: 10.1016/j.kint.2016.06.009

25. Nguyen T.C., Han Y.Y. Plasma exchange therapy for thrombotic microangiopathies. Organogenesis 2011;7(1):28–31. DOI: 10.4161/org.7.1.14027

26. Patel P., Nandwani V., Vanchiere J. et al. Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A – an associated respiratory failure and hemodynamic shock. Pediatr Crit Care Med 2011;12(2):e87–9. DOI: 10.1097/PCC.0b013e3181e2a569

27. Sokolov A.A., Sokolov D.V., Pevzner D.V. et al. Extracorporeal blood purification in the complex treatment of the novel coronavirus infection: the review of opportunities. Vestnik anesteziologii i reanimatologii = Messenger of Anesthesiology and Resuscitation. 2020;17(4):31–40. (In Russ.). DOI: 10.21292/2078­5658­2020­17­4­31­40

28. U.S. Food and Drug Administration. Emergency Use Authorizations. Available at: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ventilators.

29. Adeli S.H., Asghari A., Tabarraii R. et al. Therapeutic plasma exchange as a rescue therapy in patients with coronavirus disease 2019: a case series. Pol Arch Intern Med 2020;130(5):455–8. DOI: 10.20452/pamw.15340

30. Altmayer V., Saheb S., Rohaut B. et al. Therapeutic plasma exchange in a critically ill Covid­-19 patient. J Clin Apher 2021;36(1):179–82. DOI: 10.1002/jca.21830

31. Morath C., Weigand M.A., Zeier M. et al. Plasma exchange in critically ill COVID­19 patient. Crit Care 2020;24(1):481. DOI: 10.1186/s13054­020­03171­3

32. Fernandez J., Gratacos­Gines J., Olivas P. et al. for the Covid Clinic Critical Care (CCCC) Group Plasma Exchange. An effective rescue therapy in critically ill patients with coronavirus disease 2019 infection. Crit Care Med 2020;48(12):e1350–5. DOI: 10.1097/CCM.0000000000004613

33. Hua T., Li M., Li X. Therapeutic plasma exchange therapy support for critical COVID-­19: a case report. Ther Apher Dial 2021;25(4):533–6. DOI: 10.1111/1744­9987.13586

34. Keith P., Day M., Choe C. et al. The successful use of therapeutic plasma exchange for severe COVID-­19 acute respiratory distress syndrome with multiple organ failure. SAGE Open Med Case Rep 2020;8:2050313X20933473. DOI: 10.1177/2050313X20933473

35. Zhang L., Zhai H., Ma S. et al. Efficacy of therapeutic plasma exchange in severe COVID­-19 patients. Br J Haematol 2020;190(4):e181–3. DOI: 10.1111/bjh.16890

36. Ma J., Xia P., Zhoua Y. et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID­19. Clin Immunol 2020;214:108408. DOI: 10.1016/j.clim.2020.108408

37. Shi H., Zhou C., He P. et al. Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID­-19. Int J Antimicrob Agent 2020;56(2):105974. DOI: 10.1016/j.ijantimicag.2020.105974

38. Keith P.D., Wells A.H., Hodges J. et al. The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: a singlecenter experience. Crit Care 2020;24:518. DOI: 10.1186/s13054­020­03241­6

39. Rimmer E., Houston B.L., Kumar A. et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta­analysis. Crit Care 2014;18(6):699. DOI: 10.1186/s13054­014­0699­2

40. Knaup H., Stahl K., Schmidt B.M.W. et al. Early therapeutic plasma exchange in septic shock: a prospective open­label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care 2018;22(1):285. DOI: 10.1186/s13054­018­2220­9

41. Jaiswal V., Nasa P., Raouf M. et al. Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID­-19 – An exploratory study. Int J Infect Dis 2021;102:332–4. DOI: 10.1016/j.ijid.2020.10.085

42. Varghese J., Subramanian P., Jayanthi V. Therapeutic plasma exchange using convalescent plasma replacement therapy in severe COVID-­19 infections: a potential therapeutic option. EМJ Innov 2021;5(1):78–83.

43. Khamis F., Al­Zakwani I., Hashmi S.A. et al Therapeutic plasma exchange in adults with severe COVID­-19 infection. Int J Infect Dis 2020;99:214–8. DOI: 10.1016/j.ijid.2020.06.064

44. Kamran S.M., Mirza Z.H., Naseem A. et al. Therapeutic plasma exchange for coronavirus disease­2019 triggered cytokine release syndrome; a retrospective propensity matched control study. PLoS One 2021;16(1):e0244853. DOI: 10.1371/journal.pone.0244853

45. Kaluzhskaya K.V., Polyakov Yu.Yu., Baryakh E.A. et al. Treatment and in hospital overall survival in hematological patients with grade 4 neutropenia and coronavirus infection. Blood 2021; 138(Suppl 1):3391. DOI: 10.1182/blood­2021­147597

46. State Register of Medicines of the Ministry of Health of Russia. Available at: https://grls.rosminzdrav.ru. (In Russ.).

47. Drugs.com.

48. Kukes V.G., Sychev D.A., Andreev D.A. et al. Clinical pharmacology. M.: GEOTAR­Media, 2018. (In Russ.).